Antitumor drugs taxanes are widely used for the treatment of malignant tumors because of their remarkable biological activity and unique mechanism of action. Currently marketed taxanes include Paclitaxel injection

Paclitaxel liposome for injection

Paclitaxel for injection（albumin-bound）

Paclitaxel polymeric micelles for injection and Docetaxel injection. Due to the differences in pharmacokinetics

pharmacodynamics and toxicology caused by the optimization of the structure and the innovation of dosage form

the pharmaceutical care for different taxanes is far from each other in many aspects. To standardized and rational use of taxanes

experts from the Cancer Pharmacists Branch of Chinese Pharmacists Association

together with multidisciplanry experts from around China and under the guidance of the National Cancer Center reached the Chinese Expert Consensus on the Pharmaceutical Care for Anti-tumor Drugs Taxanes through Delphi method and expert meeting based on clinical evidence

domestic law and regulations for pharmaceutical administration and pharmaceutical care practice. Through the consensus

the whole system of pharmaceutical care is constructed

with expanded and extended pharmaceutical care for anti-tumor drugs taxanes

which provides a scientific basis for pharmacists to carry out related pharmaceutical care.